Dr. Fracasso is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
VCU Massey Cancer Center
401 College Street
Richmond, VA 23298Phone+1 804-628-0660- Is this information wrong?
Summary
- Board-certified medical oncologist, academic leader, and pharmaceutical executive with significant experience building cancer centers in academic medical centers and developing oncology drugs in biopharmaceutical companies. Expertise in preclinical, translational and clinical development of cellular and immuno-oncology therapies including clinical trial design, regulatory strategies, translational medicine, biomarkers/companion diagnostics, pharmacology, and medical oncology for the delivery of cutting-edge patient care.
Education & Training
- Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1989 - 1991
- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1984 - 1987
- Yale School of MedicineClass of 1984, MD, PhD, Alpha Omega Alpha
Certifications & Licensure
- MO State Medical License 1991 - 2025
- VA State Medical License 2007 - 2024
- PA State Medical License 2015 - 2024
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Alpha Omega Alpha
- Phi Beta Kappa
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Liposomal Doxorubicin and PSC 833 in Treating Patients With AIDS-Related Kaposi's Sarcoma or Other Advanced Cancers Start of enrollment: 1998 Mar 01
- Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based Chemotherapy Start of enrollment: 2000 Feb 01
- Oxaliplatin in Treating Patients With Recurrent or Refractory Cervical Cancer Start of enrollment: 2000 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case report.Kewen He, David S Hong, Danxia Ke, Partow Kebriaei, Tianjiao Wang, Hassan Danesi, Genevieve Bertolet, Carola Leuschner, Nahum Puebla-Osorio, Tiffany A Voss, Quan Lin, ...> ;Melanoma Research. 2023 Aug 1
- A Phase I Trial of the ABCB1 Inhibitor, Oral Valspodar, in Combination With Paclitaxel in Patients With Advanced Solid Tumors.Paula M Fracasso, George A Fisher Jr, Sherry A Goodner, Jan H Beumer, Merrill J Egorin, Carole L Fears, Jonathan D Wildi, Gary J Jones, Tillman E Pearce, Branimir I Sikic> ;American Journal of Clinical Oncology. 2023 Aug 1
- 24 citationsAutologous T cell therapy for MAGE-A4solid cancers in HLA-A*02patients: a phase 1 trial.David S Hong, Brian A Van Tine, Swethajit Biswas, Cheryl McAlpine, Melissa L Johnson, Anthony J Olszanski, Jeffrey M Clarke, Dejka Araujo, George R Blumenschein Jr, Pa...> ;Nature Medicine. 2023 Jan 1
- Join now to see all
Authored Content
- The Fast Real-Time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) Program: Innovative, High-Throughput Clinical Screening of ImmunotherapiesOctober 2018
Press Mentions
- Paula Fracasso Joins VCU Massey Cancer Center to Lead the Cancer Service LineSeptember 14th, 2022
- VCU Massey Cancer Center Names Dr. Paula Fracasso New Deputy DirectorSeptember 7th, 2022
- Global Cancer Rates in People 50 and Younger on the Rise, Study FindsSeptember 7th, 2022
- Join now to see all
Grant Support
- An Exploratory Study Of UCN-01 And Irinotecan In Advanced Triple Negative BreastNational Cancer Institute2007–2008
- Overcoming Barriers To Early Phase Clinical TrialsNational Cancer Institute2003–2004
- Oral SDZ PSC 833 And Intravenous Paclitaxel In Advanced CancerNational Center For Research Resources1998–1999
- Taxol And SDZ PSC 833 In Patients With Refractory MalignanciesNational Center For Research Resources1997–1999
- Oral SDZ PSC 833 And Intravenous Paclitaxel In Advance CancerNational Center For Research Resources1996
- Comparison Of CDNA Transcripts Of MDR Genes In The MouseNational Cancer Institute1990–1991
- Comparison Of CDNA Transcripts Of MDR Genes In The MouseNational Cancer Institute1988
Professional Memberships
- Member
- Member
- Society for Immunotherapy of Cancer - SITCMember
- Association of American Cancer InstitutesMember
Hospital Affiliations
- University of Virginia Medical CenterCharlottesville, Virginia
External Links
- Paula Fracassohttp://www.linkedin.com/in/paula-fracasso
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: